Cell & Gene Therapies

© Getty Images

Gene sequencing identifies rare pediatric disorders in Mexico

By Isabel Cameron

A new genetic sequencing technology from Element Biosciences has helped researchers from the Translational Genomics Research Institute (TGen), part of the City of Hope, identify the likely genetic causes of disorders in six of nine children from Sonora,...

© Getty Images

Donaldson acquires Univercells Technologies for €136 million

By Isabel Cameron

Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach....

© Getty Images

Insmed unveils new research platforms and capabilities

By Isabel Cameron

US biopharma Insmed has announced progress across its early-stage research programs at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.

BioMarin opens €38m expansion at Irish manufacturing site

BioMarin opens €38m expansion at Irish manufacturing site

By Rachel Arthur

BioMarin Pharmaceutical has opened the expansion of its manufacturing plant at Shanbally, Co. Cork: with the site now able to provide end-to-end manufacturing for a number of the company’s commercial products.

Pic:getty/stocktrekimages

bluebird bio submits BLA for sickle cell disease gene therapy

By Rachel Arthur

bluebird bio has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD).

A Meissner lab. Pic: Meissner

Meissner to build new $250m manufacturing facility in Athens, Georgia

By Rachel Arthur

Meissner Corporation – a company which manufactures advanced microfiltration and therapeutic manufacturing systems for pharmaceutical drugs, therapeutics, biologics, and cell and gene therapies - will invest nearly $250m in a new manufacturing facility...

Pic:getty/davidlees

Sartorius to acquire Polyplus

By Rachel Arthur

Life science group Sartorius will acquire French company Polyplus for around €2.4bn ($2.6bn).

© GettyImages/ipopba

Urgent action needed to reduce high costs of gene therapies

By Jane Byrne

The extremely high costs of gene therapies are unsustainable, and a global commitment to affordable, equitable access to these treatments is urgently needed, concluded the organising committee of a conference on human genome editing.

Pic:getty/antoniosolano

Syena sets out to pioneer TCR NK cell therapy

By Rachel Arthur

New company Syena says it has the potential to create the next generation of cell therapy: combining the safety, potency and scalability of natural killer (NK) cells with the ability of T cell receptors (TCR) to target intracellular tumor antigens.